Your browser is no longer supported. Please, upgrade your browser.
IONS Ionis Pharmaceuticals, Inc. daily Stock Chart
Ionis Pharmaceuticals, Inc.
Index- P/E52.78 EPS (ttm)0.90 Insider Own0.30% Shs Outstand139.35M Perf Week0.45%
Market Cap6.59B Forward P/E- EPS next Y-0.50 Insider Trans-24.71% Shs Float132.74M Perf Month-2.67%
Income130.50M PEG1.08 EPS next Q-0.10 Inst Own85.80% Short Float6.14% Perf Quarter-21.48%
Sales940.50M P/S7.01 EPS this Y572.90% Inst Trans-2.83% Short Ratio8.89 Perf Half Y-18.91%
Book/sh9.88 P/B4.79 EPS next Y24.30% ROA4.20% Target Price68.22 Perf Year-12.09%
Cash/sh16.87 P/C2.81 EPS next 5Y49.00% ROE9.40% 52W Range39.32 - 66.22 Perf YTD-21.64%
Dividend- P/FCF38.42 EPS past 5Y52.40% ROI13.40% 52W High-28.51% Beta1.44
Dividend %- Quick Ratio10.80 Sales past 5Y39.30% Gross Margin99.20% 52W Low20.40% ATR1.56
Employees817 Current Ratio10.90 Sales Q/Q-11.20% Oper. Margin13.70% RSI (14)46.31 Volatility2.69% 3.23%
OptionableYes Debt/Eq0.59 EPS Q/Q- Profit Margin13.90% Rel Volume0.56 Prev Close47.19
ShortableYes LT Debt/Eq0.58 EarningsNov 04 BMO Payout0.00% Avg Volume916.72K Price47.34
Recom2.60 SMA200.20% SMA50-6.19% SMA200-13.62% Volume512,815 Change0.32%
Sep-14-20Resumed JP Morgan Neutral $63
Sep-02-20Initiated The Benchmark Company Hold
Jun-01-20Resumed Oppenheimer Outperform
May-13-20Initiated RBC Capital Mkts Outperform $71
Mar-05-20Initiated Citigroup Buy $73
Dec-13-19Initiated Oppenheimer Outperform
Nov-13-19Initiated BofA/Merrill Buy $70
Nov-07-19Downgrade Morgan Stanley Equal-Weight → Underweight $63 → $48
Sep-10-19Upgrade Bernstein Mkt Perform → Outperform
Aug-08-18Reiterated Stifel Hold $48 → $47
Aug-07-18Reiterated Stifel Hold $55 → $48
May-08-18Downgrade Evercore ISI Outperform → In-line
Oct-06-17Resumed Goldman Sell $30
Aug-17-17Initiated Evercore ISI Outperform $65
Aug-09-17Reiterated Stifel Hold $42 → $50
Mar-10-17Downgrade Goldman Neutral → Sell
Dec-28-16Reiterated BMO Capital Markets Outperform $61 → $68
Dec-27-16Reiterated Leerink Partners Mkt Perform $40 → $47
Dec-27-16Reiterated Laidlaw Buy $59 → $65
Nov-10-16Resumed Leerink Partners Mkt Perform
Oct-23-20 02:05PM  
Oct-22-20 07:05AM  
Oct-21-20 07:05AM  
Oct-19-20 12:46PM  
Oct-15-20 07:05AM  
Oct-13-20 12:32PM  
Oct-12-20 09:00AM  
Oct-08-20 08:50AM  
Oct-07-20 04:54PM  
Oct-02-20 11:18AM  
Oct-01-20 04:05PM  
Sep-30-20 04:05PM  
Sep-21-20 06:45PM  
Sep-04-20 11:31AM  
Sep-03-20 07:05AM  
Sep-02-20 05:10PM  
Sep-01-20 10:14AM  
Aug-31-20 08:10PM  
Aug-29-20 04:00AM  
Aug-26-20 07:05AM  
Aug-24-20 07:00AM  
Aug-18-20 07:00AM  
Aug-13-20 07:00AM  
Aug-06-20 09:21AM  
Aug-05-20 08:55AM  
Jul-30-20 07:32PM  
Jul-29-20 12:33PM  
Jul-27-20 02:39PM  
Jul-22-20 07:05AM  
Jul-21-20 07:00AM  
Jul-20-20 07:00AM  
Jul-17-20 03:31PM  
Jul-09-20 07:00AM  
Jul-07-20 07:05AM  
Jun-17-20 07:00AM  
Jun-16-20 09:48PM  
Jun-09-20 07:00AM  
Jun-05-20 07:05AM  
May-29-20 07:03AM  
May-28-20 04:05PM  
May-19-20 09:07AM  
May-18-20 07:00AM  
May-14-20 04:05PM  
May-13-20 08:00AM  
May-08-20 06:03AM  
May-07-20 07:00AM  
May-06-20 09:45AM  
May-05-20 04:05PM  
May-01-20 07:05AM  
Apr-29-20 12:34PM  
Apr-22-20 11:08AM  
Apr-21-20 07:09AM  
Apr-20-20 07:05AM  
Apr-13-20 09:18AM  
Apr-08-20 09:56AM  
Apr-07-20 07:05AM  
Mar-23-20 12:53AM  
Mar-13-20 07:00AM  
Mar-12-20 05:46PM  
Mar-11-20 07:06AM  
Mar-05-20 08:18AM  
Mar-02-20 11:01AM  
Feb-28-20 08:09AM  
Feb-27-20 11:40AM  
Feb-26-20 08:25AM  
Feb-24-20 05:44AM  
Feb-20-20 03:59AM  
Feb-19-20 09:01PM  
Feb-13-20 07:00AM  
Feb-11-20 11:40AM  
Feb-07-20 10:00AM  
Feb-06-20 04:08PM  
Jan-30-20 02:57PM  
Jan-28-20 04:05PM  
Jan-22-20 04:29PM  
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic from ALS; ION859 for Parkinson's disease; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing severe and rare disease products, such as AKCEA-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-PKK-LRx for hereditary angioedema; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-ENAC-2.5Rx for cystic fibrosis; and ION357 for retinitis pigmentosa. In addition, its cardio metabolic and renal drugs include AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for cardiovascular diseases; AKCEA-ANGPTL3-LRx for cardio metabolic disorders; IONIS-GCGRRx for type 2 diabetes; IONIS-AGT-LRX for the treatment of resistant hyper tension; IONIS-FXI-LRx for clotting disorders; IONIS-AZ4-2.5-LRx for cardiovascular diseases; and ION839 for nonalcoholic steatohepatitis. Further, the company develops products for oncology that include IONIS-AR-2.5Rx and danvatirsen for cancers; IONIS-HBVRx and IONIS-HBV-LRx for hepatitis B virus infection; and IONIS-FB-LRx for compliment meditated disease. It has a collaboration agreement with Genuity Science, Inc. for the discovery and development of various therapeutics across a range of approximately 20 diseases. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KLEIN JOSEPH IIIDirectorOct 20Sale46.862,889135,38613,794Oct 22 05:36 PM
Hayden Michael RDirectorOct 15Option Exercise0.001,77805,334Oct 19 05:50 PM
Reikes Peter NDirectorOct 15Option Exercise0.001,77805,334Oct 19 05:46 PM
CROOKE STANLEY TExec Chairman of the BoardSep 22Sale50.4150,0002,520,460650,391Sep 23 06:44 PM
CROOKE STANLEY TExec Chairman of the BoardSep 21Sale50.182,000100,3601,581Sep 23 06:44 PM
WENDER JOSEPH HDirectorSep 16Option Exercise20.7122,500465,86388,305Sep 18 05:45 PM
Monia Brett PChief Executive OfficerSep 01Sale53.7031416,86228,879Sep 02 07:01 PM
LOSCALZO JOSEPHDirectorJul 06Option Exercise0.00667017,308Jul 06 05:49 PM
KLEIN JOSEPH IIIDirectorJul 06Option Exercise0.00667016,683Jul 06 05:32 PM
WENDER JOSEPH HDirectorJul 06Option Exercise0.00667065,805Jul 06 05:26 PM
MUTO FREDERICK TDirectorJul 06Option Exercise0.00667031,683Jul 06 05:23 PM
Castleman BreauxDirectorJul 06Option Exercise0.00667019,183Jul 06 05:30 PM
BERTHELSEN SPENCER RDirectorJul 06Option Exercise0.006670100,983Jul 06 05:25 PM
BERTHELSEN SPENCER RDirectorJul 02Option Exercise0.008890100,316Jul 06 05:25 PM
Castleman BreauxDirectorJul 02Option Exercise0.00889018,516Jul 06 05:30 PM
MUTO FREDERICK TDirectorJul 02Option Exercise0.00889031,016Jul 06 05:23 PM
WENDER JOSEPH HDirectorJul 02Option Exercise0.00889065,138Jul 06 05:26 PM
KLEIN JOSEPH IIIDirectorJul 02Option Exercise0.00889016,016Jul 06 05:32 PM
PARSHALL B LYNNEDirectorJul 02Option Exercise0.00889067,464Jul 06 05:47 PM
LOSCALZO JOSEPHDirectorJul 02Option Exercise0.00889016,641Jul 06 05:49 PM
LOSCALZO JOSEPHDirectorJul 01Option Exercise0.002,444015,752Jul 06 05:49 PM
PARSHALL B LYNNEDirectorJul 01Option Exercise0.001,778066,575Jul 06 05:47 PM
KLEIN JOSEPH IIIDirectorJul 01Option Exercise0.002,444015,127Jul 06 05:32 PM
WENDER JOSEPH HDirectorJul 01Option Exercise0.002,444064,249Jul 06 05:26 PM
Hayden Michael RDirectorJul 01Option Exercise0.001,77803,556Jul 06 06:48 PM
HERMAN JOAN EDirectorJul 01Option Exercise0.001,77805,334Jul 06 05:51 PM
MUTO FREDERICK TDirectorJul 01Option Exercise0.002,444030,127Jul 06 05:23 PM
Castleman BreauxDirectorJul 01Option Exercise0.002,444017,627Jul 06 05:30 PM
Reikes Peter NDirectorJul 01Option Exercise0.001,77803,556Jul 06 05:28 PM
BERTHELSEN SPENCER RDirectorJul 01Option Exercise0.002,444099,427Jul 06 05:25 PM
MUTO FREDERICK TDirectorJun 30Option Exercise9.2215,000138,30027,683Jul 02 05:11 PM
Castleman BreauxDirectorJun 25Option Exercise26.6610,000266,60025,183Jun 29 09:47 PM
BENNETT C FRANKEVP, Chief Scientific OfficerJun 25Option Exercise39.8715,000598,05047,364Jun 29 09:47 PM
Castleman BreauxDirectorJun 25Sale60.0010,000600,00015,183Jun 29 09:47 PM
BENNETT C FRANKEVP, Chief Scientific OfficerJun 25Sale59.7715,000896,50532,364Jun 29 09:47 PM
CROOKE STANLEY TExec Chairman of the BoardJun 25Sale60.119,914595,9072,021Jun 26 07:47 PM
CROOKE STANLEY TExec Chairman of the BoardJun 24Sale58.805,000294,00011,935Jun 26 07:47 PM
BERTHELSEN SPENCER RDirectorJun 23Option Exercise9.2215,000138,300111,983Jun 25 07:28 PM
BERTHELSEN SPENCER RDirectorJun 23Sale58.7615,000881,40096,983Jun 25 07:28 PM
CROOKE STANLEY TExec Chairman of the BoardJun 19Sale58.3310,000583,25016,935Jun 19 07:03 PM
CROOKE STANLEY TExec Chairman of the BoardJun 17Sale58.252,000116,5003,581Jun 19 07:03 PM
CROOKE STANLEY TExec Chairman of the BoardJun 17Sale57.9015,000868,52126,935Jun 19 07:03 PM
HERMAN JOAN EDirectorJun 10Option Exercise0.003,55603,556Jun 17 08:15 PM
CROOKE STANLEY TExec Chairman of the BoardMar 25Sale47.001,00047,0005,581Mar 27 07:05 PM
CROOKE STANLEY TExec Chairman of the BoardMar 25Sale47.0015,000705,00041,935Mar 27 07:05 PM
CROOKE STANLEY TExec Chairman of the BoardMar 19Sale45.001,00045,0006,581Mar 23 06:17 PM
CROOKE STANLEY TExec Chairman of the BoardMar 19Sale45.1715,000677,54656,545Mar 23 06:17 PM
CROOKE STANLEY TExec Chairman of the BoardMar 17Sale44.7520,390912,35571,545Mar 19 01:55 PM
O'NEIL PATRICK R.SVP & General CounselFeb 10Sale59.603,882231,36720,720Feb 11 05:40 PM
Swayze EricSVP, ResearchJan 15Option Exercise0.006,52207,290Jan 17 06:47 PM
PARSHALL B LYNNEDirectorJan 15Option Exercise0.0015,136068,702Jan 17 06:42 PM
O'NEIL PATRICK R.SVP, Legal & General CounselJan 15Option Exercise0.0012,045028,879Jan 17 06:39 PM
Monia Brett PChief Executive OfficerJan 15Option Exercise0.0019,921036,206Jan 17 06:36 PM
HOUGEN ELIZABETH LSVP, Finance & CFOJan 15Option Exercise0.0012,044036,504Jan 17 06:33 PM
Geary Richard SSVP, DevelopmentJan 15Option Exercise0.0013,139034,722Jan 17 06:30 PM
CROOKE STANLEY TExecutive Chairman of BoardJan 15Option Exercise0.003,31708,849Jan 17 06:28 PM
CROOKE STANLEY TExecutive Chairman of BoardJan 15Option Exercise0.0039,6430109,277Jan 17 06:28 PM
BENNETT C FRANKChief Scientific OfficerJan 15Option Exercise0.0011,711036,357Jan 17 06:11 PM
Monia Brett PChief Executive OfficerJan 02Sale60.2517310,42316,285Jan 03 07:04 PM
KLEIN JOSEPH IIIDirectorDec 23Option Exercise35.531,00035,53013,683Dec 23 07:28 PM
KLEIN JOSEPH IIIDirectorDec 23Sale61.871,00061,87412,683Dec 23 07:28 PM
HOUGEN ELIZABETH LSVP, Finance & CFODec 20Option Exercise10.8210,634115,06027,251Dec 20 07:23 PM
KLEIN JOSEPH IIIDirectorDec 16Option Exercise35.531,00035,53013,683Dec 18 05:07 PM
KLEIN JOSEPH IIIDirectorDec 16Sale65.451,00065,44712,683Dec 18 05:07 PM
KLEIN JOSEPH IIIDirectorDec 09Option Exercise35.531,00035,53013,683Dec 10 06:54 PM
KLEIN JOSEPH IIIDirectorDec 09Sale63.741,00063,74512,683Dec 10 06:54 PM
Geary Richard SSVP, DevelopmentDec 04Option Exercise14.6910,000146,90031,583Dec 05 05:26 PM
HOUGEN ELIZABETH LSVP, Finance & CFODec 04Option Exercise10.824,56649,40424,117Dec 05 05:31 PM
HOUGEN ELIZABETH LSVP, Finance & CFODec 04Sale65.004,566296,79020,055Dec 05 05:31 PM
Geary Richard SSVP, DevelopmentDec 04Sale65.0010,000650,00021,583Dec 05 05:26 PM
Geary Richard SSVP, DevelopmentDec 02Option Exercise14.695,00073,45026,583Dec 04 06:22 PM
KLEIN JOSEPH IIIDirectorDec 02Option Exercise35.531,00035,53013,683Dec 04 06:26 PM
KLEIN JOSEPH IIIDirectorDec 02Sale64.081,00064,08312,683Dec 04 06:26 PM
Geary Richard SSVP, DevelopmentDec 02Sale65.065,000325,28721,583Dec 04 06:22 PM
HOUGEN ELIZABETH LSVP, Finance & CFONov 25Option Exercise10.824,00043,28024,055Nov 26 05:40 PM
KLEIN JOSEPH IIIDirectorNov 25Sale62.9081251,07512,683Nov 26 05:43 PM
HOUGEN ELIZABETH LSVP, Finance & CFONov 25Sale62.504,000250,00020,055Nov 26 05:40 PM
KLEIN JOSEPH IIIDirectorNov 20Sale60.002,000120,00013,495Nov 21 06:40 PM
Monia Brett PCOO & SVP, Translational MedNov 20Sale60.015,776346,61816,458Nov 21 06:38 PM
HOUGEN ELIZABETH LSVP, Finance & CFONov 19Option Exercise10.824,00043,28024,055Nov 21 06:36 PM
HOUGEN ELIZABETH LSVP, Finance & CFONov 19Sale58.804,000235,20020,055Nov 21 06:36 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.